BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol 2012;7:107-16. [PMID: 22707276 DOI: 10.1007/s11523-012-0219-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Pellat A, Coriat R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. J Clin Med. 2020;9. [PMID: 32492939 DOI: 10.3390/jcm9061677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
3 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Reference Citation Analysis]
4 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
5 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Reference Citation Analysis]
6 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Reference Citation Analysis]
7 Maxwell JE, Sherman SK, Menda Y, Wang D, O'Dorisio TM, Howe JR. Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. J Surg Res. 2014;190:548-553. [PMID: 24950794 DOI: 10.1016/j.jss.2014.05.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
8 de Mestier L, Deguelte-lardière S, Brixi H, Kianmanesh R, Cadiot G. Tumeurs neuroendocrines digestives. La Revue de Médecine Interne 2016;37:551-60. [DOI: 10.1016/j.revmed.2016.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol 2018;79:109-15. [PMID: 29763717 DOI: 10.1016/j.humpath.2018.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
10 Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017;6:44-8. [PMID: 28123727 DOI: 10.3892/mco.2016.1097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18:459-471. [PMID: 28975561 DOI: 10.1007/s11154-017-9431-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
12 Choi AB, Maxwell JE, Keck KJ, Bellizzi AJ, Dillon JS, OʼDorisio TM, Howe JR. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors? Pancreas 2017;46:1115-20. [PMID: 28902780 DOI: 10.1097/MPA.0000000000000911] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
13 Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O'Dorisio TM, Howe J, Button A, Zamba G, Halfdanarson TR. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43:219-225. [PMID: 24518499 DOI: 10.1097/mpa.0000000000000030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
14 Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16. [PMID: 30009041 DOI: 10.1186/s40842-018-0066-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
15 Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol 2017;18:72. [PMID: 29143892 DOI: 10.1007/s11864-017-0514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Dermine S, Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019;8. [PMID: 31703375 DOI: 10.3390/jcm8111907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]